The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback